The state-controlled pharmaceutical holding company, PT Bio Farma, announced the company is conducting a clinical trial for the COVID-19 vaccine from China's Sinovac Biotech for the next six months. It will be ready for domestic use as early next year.
Bio Farma president director Honesti Basyir said the company was ready to launch a Phase III clinical trial before the officials authorize its widespread usage. "If the third stage of the clinical trial of COVID-19 vaccine runs smoothly, Bio Farma will produce it in the first quarter of 2021. We have prepared a production facility at Bio Farma, with a maximum production capacity of 250 million doses," Honesti said in a statement.
Bio Farma chose Sinovac as a partner due to its vaccine platform or the manufacturing method employed by Sinovac at par with its competencies. Bio Farma has experience in manufacturing vaccines through the use of the inactivation method, including the Pertussis vaccine.
The Covid-19 vaccine clinical trial will be commenced soon at Clinical Test Center, the Faculty of Medicine, Padjajaran University. The test will take 1,620 subjects with an age range between 18-59 years, that meet specific criteria. Simultaneously, the remainder of the vaccine will be used for lab tests in several laboratories, including Bio Farma and the National Food and Drug Testing Center (PPOMN).